Feedback PLC Study Results
20 July 2015 - 4:00PM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
20 July 2015
20 July 2015
Feedback plc
("Feedback" or the "Company")
Study Results
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce the successful completion of a large
evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy
imaging biomarker in 241 metastatic renal (kidney) cell cancer
(m-RCC) patients treated with anti-angiogenic therapy (AAT - drugs
that block cancer blood-vessel growth). This research study was led
by Dr. Andrew Smith (Associate Professor in Radiology and Director
of Radiology Research) along with colleagues from the University of
Mississippi Medical Center, Jackson, Mississippi, USA (UMMC).
Specifically the results from this large study demonstrate that
TexRAD texture analysis on conventional CT imaging acquired before
m-RCC patients underwent AAT was a very strong predictor of overall
survival at 2 years. Dr. Smith and colleagues further demonstrated
that in a multivariate model comprising of known clinical
biomarkers in this cancer population, TexRAD CTTA additionally
demonstrated to be a strongly independent predictor of overall
survival. The authors have developed a "new prognostic risk index"
comprising of TexRAD CTTA and other known clinical factors which
has demonstrated superior accuracy in predicting patient survival
and classified patients into low, medium and high-risk groups with
strong statistical significance (p<0.0001). Dr. Smith and
colleagues also concluded that pre-therapy TexRAD CTTA is a
significant prognostic marker in patients with m-RCC treated with
AAT.
Dr Andrew Smith commented:
"Increasing the accuracy of pre-therapy prognostic risk models
with new imaging biomarkers such as TexRAD CTTA can be used as a
way of improving clinical trial and pre-treatment planning for
patients with m-RCC treated with AAT"
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"We are delighted with the positive results from the large study
undertaken by our eminent collaborator/customer at UMMC, Dr Andrew
Smith and the team at Mississippi, USA. This is a very important
study demonstrating the specific application of TexRAD CT texture
analysis as a non-invasive imaging biomarker in the management of
m-RCC patients treated with AAT. AAT is expensive and increases
toxicity and potential side-effects, so being able to select those
patients who are likely to respond well and stand to have an
overall survival benefit, before treatment has started, will allow
for better and more cost-effective patient management. This type of
precision medicine results in improved patient outcomes and overall
efficacy."
Dr Smith and colleagues submitted an abstract, which has now
been accepted, and Dr. Smith will further present the work as an
oral presentation at the annual meeting of the Society of Computed
Body Tomography and Magnetic Resonance in Toronto, Canada between
October 7-11 2015 (http://www.scbtmr.org).
For further information contact:
Feedback plc Tel: 01954 718072
Simon Barrell / Trevor Brown /
Tom Charlton
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an
'Imaging-Biomarker') in confident decision-making: it has the
potential to assess the prognosis, disease-severity (e.g. risk of
metastases) and response evaluation of patients with cancer.
Currently TexRAD research has shown great potential in many
different oncological sites, including, colorectal, breast, lung,
prostate, oesophageal, head & neck, lymphoma, liver and renal
cancers and could potentially be employed as a heterogeneity
assessing tool in the era of 'Precision and Personalized Medicine'.
TexRAD is manufactured under licence by company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABKLLFEDFBBBQ
Feedback (LSE:FDBK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024